Item 1.01 Entry into a Material Definitive Agreement.
As previously announced, on
Purchaser's obligation to accept for payment shares of Common Stock validly tendered pursuant to the Offer is subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, including: that (i) there be validly tendered and not validly withdrawn prior to the expiration of the Offer a number of shares of Common Stock that, considered together with all other shares of Common Stock (if any) beneficially owned by Parent and its affiliates, represent one more share of Common Stock than 50% of the total number of shares of Common Stock outstanding at the expiration of the Offer; (ii) the waiting period (and any extension thereof) applicable to the transactions contemplated by the Merger Agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), has expired or been terminated; (iii) the accuracy of the representations and warranties of the Company contained in the Merger Agreement, subject to customary thresholds and exceptions; (iv) the Company's compliance with, or performance of, in all material respects its covenants and agreements contained in the Merger Agreement; (v) the absence of a Material Adverse Effect (as defined in the Merger Agreement); and (vi) other customary conditions set forth in Annex I of the Merger Agreement.
Following the consummation of the Offer, subject to the conditions set forth in
the Merger Agreement, and in accordance with the General Corporation Law of the
The Merger Agreement also provides an alternative means by which the Merger may be consummated even if the Offer is not completed, which requires the approval of the Company's stockholders. Pursuant to the Merger Agreement, in certain circumstances Purchaser may elect to proceed with the acquisition through a Merger without any Offer, in which case Purchaser will terminate the Offer or allow it to expire (such termination, an "Offer Termination"). In this case the Company would be required to file a proxy statement to obtain approval of the Merger by the Company's stockholders at a special stockholders meeting held for the purpose of voting upon the adoption of the Merger Agreement, and the Merger would be effected pursuant to Section 251(c) of the DGCL.
--------------------------------------------------------------------------------
Pursuant to the Merger, each issued and outstanding share of Common Stock (other
than (i) shares of Common Stock with respect to which the holders thereof have
properly exercised and perfected demands for appraisal of such shares in
accordance with the DGCL, (ii) shares of Common Stock that are owned by the
Company as treasury stock, and (iii) shares of Common Stock then held by Parent
or Purchaser) will be converted automatically into and will thereafter represent
only the right to receive
In addition, immediately prior to the effective time of the Merger (the "Effective Time"), by virtue of the Merger and without any action on the part of any holder thereof, each outstanding and unexercised option of the Company, whether or not vested, that has a per share exercise price that is less than the Merger Consideration (as defined in the Merger Agreement) (an "In the Money Option") shall be cancelled and the holder thereof shall be entitled to receive a cash payment equal to (A) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share under such option, multiplied by (B) the total number of shares subject to such option immediately prior to the Effective Time (without regard to vesting).
At the Effective Time, each Company option other than an In the Money Option that is then outstanding and unexercised, whether or not vested, shall be cancelled with no consideration payable in respect thereof.
The Merger Agreement includes customary representations, warranties and covenants of the Company, Parent and Merger Sub for a transaction of this nature, including covenants regarding the operation of the Company's business prior to the Effective Time.
The Company has agreed to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations with third parties regarding acquisition proposals. Notwithstanding these restrictions, the Company may under certain circumstances provide information to and participate in discussions or negotiations with third parties with respect to an unsolicited bona fide written acquisition proposal that the board of directors of the Company has determined constitutes or would reasonably be expected to lead to a Superior Offer (as such term is defined in the Merger Agreement), if failing to do so would be inconsistent with the board of director's fiduciary duties under applicable law.
The Merger Agreement also provides that, in connection with the termination of
the Merger Agreement under specified circumstances, including termination by the
Company to accept and enter into an agreement with respect to a Superior Offer,
the Company will be required to pay Parent a termination fee in the amount of
The board of directors of the Company has unanimously (i) determined that the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Offer and the Merger are fair to and in the best interest of the Company and its stockholders, (ii) declared it advisable that the Company enters into the Merger Agreement, (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation by the Company of the Transactions, including the Offer and the Merger, (iv) resolved that (a) if the Offer Acceptance Time (as defined in the Merger Agreement) occurs, the Merger shall be effected under Section 251(h) of the DGCL and will be effected as soon as practicable following the consummation of the Offer, and (b) if an Offer Termination occurs, the Merger will be governed by Section 251(c) of the DGCL, in each case, upon the terms and subject to the conditions set forth in the Merger Agreement and (v) resolved to recommend that the Company's stockholders (1) accept the Offer and tender their shares of Common Stock to Purchaser pursuant to the Offer and (2) adopt the Merger Agreement at any meeting of the Company's stockholders held for such purpose and any adjournment or postponement thereof.
The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K, and is incorporated herein by reference. A copy of the Merger Agreement has been included to provide investors with information regarding its terms and is not intended to provide any factual information about the Company or Parent.
--------------------------------------------------------------------------------
The Merger Agreement contains representations, warranties, covenants and agreements, which were made only for purposes of such agreement and as of specified dates. The representations and warranties in the Merger Agreement reflect negotiations between the parties to the Merger Agreement and are not intended as statements of fact to be relied upon by the Company's stockholders. In particular, the representations, warranties, covenants and agreements in the Merger Agreement may be subject to limitations agreed by the parties, including having been modified or qualified by certain confidential disclosures that were made between the parties in connection with the negotiation of the Merger Agreement, and having been made for purposes of allocating risk among the parties rather than establishing matters of fact. In addition, the parties may apply standards of materiality in a way that is different from what may be viewed as material by investors. As such, the representations and warranties in the Merger Agreement may not describe the actual state of affairs at the date they were made or at any other time and you should not rely on them as statements of fact. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, and unless required by applicable law, the Company undertakes no obligation to update such information.
Tender and Support Agreement
In connection with the execution of the Merger Agreement, each of
The form of Tender and Support Agreement has been included to provide
information regarding its terms. It is not intended to modify or supplement any
factual disclosures about the applicable stockholder or the Company, Parent or
Purchaser in any public reports filed with the
The foregoing description of the Tender and Support Agreement does not purport to be complete and is qualified in their entirety by reference to the full text of the Tender and Support Agreement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
Forward-Looking Statements
This communication includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of Regeneron
Pharmaceuticals, Inc. ("Regeneron") and
--------------------------------------------------------------------------------
Regeneron's and Checkmate's ability to manage their supply chains; Regeneron's ability to manage net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"); the nature, timing, and possible success and therapeutic applications of Regeneron's Products, product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates"), and product candidates being developed by Checkmate, such as vidutolimod; the extent to which the results from the research and development programs conducted by Regeneron, Checkmate, and/or their collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of the Toll-like receptor 9 . . .
Item 9.01 Financial Statements and Exhibits
(d) Exhibits Exhibit No. Description of Exhibit 2.1 Agreement and Plan of Merger, dated as ofApril 18, 2022 , by and amongCheckmate Pharmaceuticals, Inc. , Regeneron Pharmaceuticals, Inc., andScandinavian Acquisition Sub, Inc. * 99.1 Tender and Support Agreement, dated as ofApril 18, 2022 by and among Regeneron Pharmaceuticals, Inc.,Scandinavian Acquisition Sub, Inc. and certain Stockholders ofCheckmate Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The
Company hereby undertakes to furnish supplemental copies of any of the omitted
schedules upon request by the
provided, that the Company may request confidential treatment pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so
furnished.
--------------------------------------------------------------------------------
© Edgar Online, source